Zelira Therapeutics Ltd
ASX:ZLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vestum AB (publ)
STO:VESTUM
|
SE |
|
China Oil Hbp Science & Technology Co Ltd
SZSE:002554
|
CN |
Zelira Therapeutics Ltd
EPS (Diluted)
Zelira Therapeutics Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zelira Therapeutics Ltd
ASX:ZLD
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
40%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
EPS (Diluted)
-AU$1
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Zelira Therapeutics Ltd
Glance View
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The firm's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.
See Also
What is Zelira Therapeutics Ltd's EPS (Diluted)?
EPS (Diluted)
-0.3
AUD
Based on the financial report for Jun 30, 2025, Zelira Therapeutics Ltd's EPS (Diluted) amounts to -0.3 AUD.
What is Zelira Therapeutics Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
26%
Over the last year, the EPS (Diluted) growth was 90%. The average annual EPS (Diluted) growth rates for Zelira Therapeutics Ltd have been 40% over the past three years , 26% over the past five years .
